Limits...
A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis.

Wang L, Guo GY, Wang JB, Zhou XM, Yang Q, Han ZY, Li Q, Zhang JW, Cai Y, Ren XL, Zhou X, Chen RR, Shi YQ, Han Y, Fan DM - Sci Rep (2015)

Bottom Line: We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014).Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant.However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders.

View Article: PubMed Central - PubMed

Affiliation: Division of Hepatology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xian, 710032, Shaanxi Province, China.

ABSTRACT
Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. We have previously reported that augmented expression of lysosome-associated membrane protein 2 (LAMP-2) was correlated with the severity of PBC. This study aimed to determine whether serum LAMP-2 could serve as a predictor of biochemical response to UDCA. The efficiency of serum LAMP-2 to predict biochemical response was assessed after 1 year of UDCA treatment in PBC patients by a retrospective analysis. We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014). Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant. However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders. Further studies showed that the 35% decline of LAMP-2 after treatment for 3 months could be stated as an indicator of UDCA response with the sensitivity of 62.9% and specificity of 75.0% by Paris criteria. Meanwhile the specificity and sensitivity were identified as 63.5% and 64.1% by Barcelona criteria. Together, a decline in LAMP-2 might help to predict the response to UDCA.

No MeSH data available.


Related in: MedlinePlus

Baseline serum LAMP-2 levels in responders and non-responders and rates of biochemical response in low and high LAMP-2 groups.(a, b) The pretreatment serum LAMP-2 levels were higher in non-responders, but no significant differences were observed. (c, d) The rates of biochemical response were higher in low LAMP-2 group, but the differences were statistically insignificant. The biochemical responses were evaluated by Paris Definitions (a and c) or by Barcelona Definitions (b and d). Data are expressed as median with interquartile range in a and b.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4403591&req=5

f2: Baseline serum LAMP-2 levels in responders and non-responders and rates of biochemical response in low and high LAMP-2 groups.(a, b) The pretreatment serum LAMP-2 levels were higher in non-responders, but no significant differences were observed. (c, d) The rates of biochemical response were higher in low LAMP-2 group, but the differences were statistically insignificant. The biochemical responses were evaluated by Paris Definitions (a and c) or by Barcelona Definitions (b and d). Data are expressed as median with interquartile range in a and b.

Mentions: To examine whether pretreatment serum LAMP-2 level could serve as a predictor of biochemical response to UDCA, we evaluated the baseline serum LAMP-2 in responders and non-responders. The Paris and Barcelona definitions of the 1-year biochemical response were independently utilized as criteria79. In our cohort, the rates of biochemical response were 68.6% (70/102) when defined by Paris criteria and 61.8% (63/102) by Barcelona criteria. The pretreatment levels of LAMP-2 were higher in non-responders than that in responders by Paris criteria (1023.14 ng/ml in average, ranged from 567.42-1382.21 versus 831.70 ng/ml in average, ranged from 507.55-939.03, p = 0.282) and by Barcelona criteria (996.77 ng/ml in average, ranged from 643.48-1352.56 versus 805.50 ng/ml in average, ranged from 471.45-864.14, p = 0.131), although no significant differences were observed (Figs. 2a and b). We then divided the patients with PBC into low (< 786 ng/ml) and high (≥ 786 ng/ml) LAMP-2 groups based on median pretreatment serum LAMP-2 level. The rates of biochemical response were 76.0% in low and 61.5% in high LAMP-2 group by Paris criteria (p = 0.116), while 70.8% in low and 57.3% in high LAMP-2 group by Barcelona criteria (p = 0.076) (Figs. 2c and d). These data indicated that pretreatment serum levels of LAMP-2 could not be exclusively and statistically associated with response to UDCA. The baseline serum LAMP-2 may not independently predict the response to UDCA treatment.


A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis.

Wang L, Guo GY, Wang JB, Zhou XM, Yang Q, Han ZY, Li Q, Zhang JW, Cai Y, Ren XL, Zhou X, Chen RR, Shi YQ, Han Y, Fan DM - Sci Rep (2015)

Baseline serum LAMP-2 levels in responders and non-responders and rates of biochemical response in low and high LAMP-2 groups.(a, b) The pretreatment serum LAMP-2 levels were higher in non-responders, but no significant differences were observed. (c, d) The rates of biochemical response were higher in low LAMP-2 group, but the differences were statistically insignificant. The biochemical responses were evaluated by Paris Definitions (a and c) or by Barcelona Definitions (b and d). Data are expressed as median with interquartile range in a and b.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4403591&req=5

f2: Baseline serum LAMP-2 levels in responders and non-responders and rates of biochemical response in low and high LAMP-2 groups.(a, b) The pretreatment serum LAMP-2 levels were higher in non-responders, but no significant differences were observed. (c, d) The rates of biochemical response were higher in low LAMP-2 group, but the differences were statistically insignificant. The biochemical responses were evaluated by Paris Definitions (a and c) or by Barcelona Definitions (b and d). Data are expressed as median with interquartile range in a and b.
Mentions: To examine whether pretreatment serum LAMP-2 level could serve as a predictor of biochemical response to UDCA, we evaluated the baseline serum LAMP-2 in responders and non-responders. The Paris and Barcelona definitions of the 1-year biochemical response were independently utilized as criteria79. In our cohort, the rates of biochemical response were 68.6% (70/102) when defined by Paris criteria and 61.8% (63/102) by Barcelona criteria. The pretreatment levels of LAMP-2 were higher in non-responders than that in responders by Paris criteria (1023.14 ng/ml in average, ranged from 567.42-1382.21 versus 831.70 ng/ml in average, ranged from 507.55-939.03, p = 0.282) and by Barcelona criteria (996.77 ng/ml in average, ranged from 643.48-1352.56 versus 805.50 ng/ml in average, ranged from 471.45-864.14, p = 0.131), although no significant differences were observed (Figs. 2a and b). We then divided the patients with PBC into low (< 786 ng/ml) and high (≥ 786 ng/ml) LAMP-2 groups based on median pretreatment serum LAMP-2 level. The rates of biochemical response were 76.0% in low and 61.5% in high LAMP-2 group by Paris criteria (p = 0.116), while 70.8% in low and 57.3% in high LAMP-2 group by Barcelona criteria (p = 0.076) (Figs. 2c and d). These data indicated that pretreatment serum levels of LAMP-2 could not be exclusively and statistically associated with response to UDCA. The baseline serum LAMP-2 may not independently predict the response to UDCA treatment.

Bottom Line: We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014).Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant.However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders.

View Article: PubMed Central - PubMed

Affiliation: Division of Hepatology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xian, 710032, Shaanxi Province, China.

ABSTRACT
Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. We have previously reported that augmented expression of lysosome-associated membrane protein 2 (LAMP-2) was correlated with the severity of PBC. This study aimed to determine whether serum LAMP-2 could serve as a predictor of biochemical response to UDCA. The efficiency of serum LAMP-2 to predict biochemical response was assessed after 1 year of UDCA treatment in PBC patients by a retrospective analysis. We found that the basal serum LAMP-2 level was increased in PBC, especially in patients with stage III-IV (p = 0.010) or TBIL > 1 mg/dL (p = 0.014). Baseline serum LAMP-2 was higher in non-responders than that in responders, but the difference was statistically insignificant. However, after UDCA treatment, serum LAMP-2 level decreased prominently in the first 3 months, which was more obvious in responders. Further studies showed that the 35% decline of LAMP-2 after treatment for 3 months could be stated as an indicator of UDCA response with the sensitivity of 62.9% and specificity of 75.0% by Paris criteria. Meanwhile the specificity and sensitivity were identified as 63.5% and 64.1% by Barcelona criteria. Together, a decline in LAMP-2 might help to predict the response to UDCA.

No MeSH data available.


Related in: MedlinePlus